{
     "PMID": "27334276",
     "OWN": "NLM",
     "STAT": "MEDLINE",
     "DCOM": "20170320",
     "LR": "20170916",
     "IS": "1439-099X (Electronic) 0179-7158 (Linking)",
     "VI": "192",
     "IP": "11",
     "DP": "2016 Nov",
     "TI": "Intensity-modulated proton therapy, volumetric-modulated arc therapy, and 3D conformal radiotherapy in anaplastic astrocytoma and glioblastoma : A dosimetric comparison.",
     "PG": "770-779",
     "AB": "PURPOSE: The prognosis for high-grade glioma (HGG) patients is poor; thus, treatment-related side effects need to be minimized to conserve quality of life and functionality. Advanced techniques such as proton radiation therapy (PRT) and volumetric-modulated arc therapy (VMAT) may potentially further reduce the frequency and severity of radiogenic impairment. MATERIALS AND METHODS: We retrospectively assessed 12 HGG patients who had undergone postoperative intensity-modulated proton therapy (IMPT). VMAT and 3D conformal radiotherapy (3D-CRT) plans were generated and optimized for comparison after contouring crucial neuronal structures important for neurogenesis and neurocognitive function. Integral dose (ID), homogeneity index (HI), and inhomogeneity coefficient (IC) were calculated from dose statistics. Toxicity data were evaluated. RESULTS: Target volume coverage was comparable for all three modalities. Compared to 3D-CRT and VMAT, PRT showed statistically significant reductions (p < 0.05) in mean dose to whole brain (-20.2 %, -22.7 %); supratentorial (-14.2 %, -20,8 %) and infratentorial (-91.0 %, -77.0 %) regions; brainstem (-67.6 %, -28.1 %); pituitary gland (-52.9 %, -52.5 %); contralateral hippocampus (-98.9 %, -98.7 %); and contralateral subventricular zone (-62.7 %, -66.7 %, respectively). Fatigue (91.7 %), radiation dermatitis (75.0 %), focal alopecia (100.0 %), nausea (41.7 %), cephalgia (58.3 %), and transient cerebral edema (16.7 %) were the most common acute toxicities. CONCLUSION: Essential dose reduction while maintaining equal target volume coverage was observed using PRT, particularly in contralaterally located critical neuronal structures, areas of neurogenesis, and structures of neurocognitive functions. These findings were supported by preliminary clinical results confirming the safety and feasibility of PRT in HGG.",
     "FAU": [
          "Adeberg, S",
          "Harrabi, S B",
          "Bougatf, N",
          "Bernhardt, D",
          "Rieber, J",
          "Koerber, S A",
          "Syed, M",
          "Sprave, T",
          "Mohr, A",
          "Abdollahi, A",
          "Haberer, T",
          "Combs, S E",
          "Herfarth, K",
          "Debus, J",
          "Rieken, S"
     ],
     "AU": [
          "Adeberg S",
          "Harrabi SB",
          "Bougatf N",
          "Bernhardt D",
          "Rieber J",
          "Koerber SA",
          "Syed M",
          "Sprave T",
          "Mohr A",
          "Abdollahi A",
          "Haberer T",
          "Combs SE",
          "Herfarth K",
          "Debus J",
          "Rieken S"
     ],
     "AD": "Heidelberg Institute of Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120, Heidelberg, Germany. Sebastian.adeberg@med.uni-heidelberg.de. Heidelberg Ion-Beam Therapy Center (HIT), Im Neuenheimer Feld 450, 69120, Heidelberg, Germany. Sebastian.adeberg@med.uni-heidelberg.de. Department of Radiation Oncology, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany. Sebastian.adeberg@med.uni-heidelberg.de. Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120, Heidelberg, Germany. Sebastian.adeberg@med.uni-heidelberg.de. Heidelberg Institute of Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120, Heidelberg, Germany. Heidelberg Ion-Beam Therapy Center (HIT), Im Neuenheimer Feld 450, 69120, Heidelberg, Germany. Department of Radiation Oncology, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany. Heidelberg Institute of Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120, Heidelberg, Germany. Heidelberg Ion-Beam Therapy Center (HIT), Im Neuenheimer Feld 450, 69120, Heidelberg, Germany. Department of Radiation Oncology, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany. Heidelberg Institute of Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120, Heidelberg, Germany. Department of Radiation Oncology, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany. Heidelberg Institute of Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120, Heidelberg, Germany. Heidelberg Ion-Beam Therapy Center (HIT), Im Neuenheimer Feld 450, 69120, Heidelberg, Germany. Department of Radiation Oncology, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany. Heidelberg Institute of Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120, Heidelberg, Germany. Heidelberg Ion-Beam Therapy Center (HIT), Im Neuenheimer Feld 450, 69120, Heidelberg, Germany. Department of Radiation Oncology, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany. Heidelberg Institute of Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120, Heidelberg, Germany. Department of Radiation Oncology, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany. Heidelberg Institute of Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120, Heidelberg, Germany. Department of Radiation Oncology, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany. Heidelberg Institute of Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120, Heidelberg, Germany. Department of Radiation Oncology, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany. Department of Radiation Oncology, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany. Heidelberg Institute of Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120, Heidelberg, Germany. Heidelberg Ion-Beam Therapy Center (HIT), Im Neuenheimer Feld 450, 69120, Heidelberg, Germany. Department of Radiation Oncology, Technische Universitat Munchen, Ismaninger Strasse 22, 81675, Munchen, Germany. Institut fur Innovative Radiotherapie (iRT), Department of Radiation Sciences (DRS), Helmholtz Zentrum Munchen, Ingostadter Landtrasse 1, Neuherberg, Germany. Heidelberg Institute of Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120, Heidelberg, Germany. Heidelberg Ion-Beam Therapy Center (HIT), Im Neuenheimer Feld 450, 69120, Heidelberg, Germany. Department of Radiation Oncology, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany. Heidelberg Institute of Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120, Heidelberg, Germany. Heidelberg Ion-Beam Therapy Center (HIT), Im Neuenheimer Feld 450, 69120, Heidelberg, Germany. Department of Radiation Oncology, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany. Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120, Heidelberg, Germany. Heidelberg Institute of Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120, Heidelberg, Germany. Heidelberg Ion-Beam Therapy Center (HIT), Im Neuenheimer Feld 450, 69120, Heidelberg, Germany. Department of Radiation Oncology, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.",
     "LA": [
          "eng"
     ],
     "PT": [
          "Comparative Study",
          "Journal Article"
     ],
     "TT": "Intensitatsmodulierte Protonentherapie, volumenmodulierte Arc-Therapie und dreidimensionale konformale Radiotherapie beim anaplastischen Astrozytom und Glioblastom : Ein dosimetrischer Vergleich.",
     "DEP": "20160622",
     "PL": "Germany",
     "TA": "Strahlenther Onkol",
     "JT": "Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]",
     "JID": "8603469",
     "SB": "IM",
     "MH": [
          "Adult",
          "Astrocytoma/*radiotherapy",
          "Brain Injuries/etiology/prevention & control",
          "Brain Neoplasms/*radiotherapy",
          "Cranial Irradiation/adverse effects/methods",
          "Female",
          "Glioblastoma/*radiotherapy",
          "Humans",
          "Male",
          "Middle Aged",
          "Organs at Risk/radiation effects",
          "Proton Therapy/adverse effects/*methods",
          "Radiation Exposure",
          "Radiation Injuries/etiology/prevention & control",
          "Radiation Protection/methods",
          "*Radiotherapy Dosage",
          "Radiotherapy Planning, Computer-Assisted/methods",
          "Radiotherapy, Intensity-Modulated/adverse effects/*methods",
          "Retrospective Studies",
          "Treatment Outcome"
     ],
     "OTO": [
          "NOTNLM"
     ],
     "OT": [
          "*Brain tumors",
          "*Neurogenesis",
          "*Organs at risk",
          "*Quality of life",
          "*Toxicity"
     ],
     "EDAT": "2016/10/27 06:00",
     "MHDA": "2017/03/21 06:00",
     "CRDT": [
          "2016/06/24 06:00"
     ],
     "PHST": [
          "2016/03/22 00:00 [received]",
          "2016/05/20 00:00 [accepted]",
          "2016/10/27 06:00 [pubmed]",
          "2017/03/21 06:00 [medline]",
          "2016/06/24 06:00 [entrez]"
     ],
     "AID": [
          "10.1007/s00066-016-1007-7 [doi]",
          "10.1007/s00066-016-1007-7 [pii]"
     ],
     "PST": "ppublish",
     "SO": "Strahlenther Onkol. 2016 Nov;192(11):770-779. doi: 10.1007/s00066-016-1007-7. Epub 2016 Jun 22.",
     "term": "hippocampus"
}